Method Improves Risk Assessment for Lung Cancer Screening
The approach improved risk assessment compared with 2021 USPSTF screening criteria.
The approach improved risk assessment compared with 2021 USPSTF screening criteria.
This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of small cell lung cancer.
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.
A detailed smoking history may help to inform patient outcomes.
A practice improvement project increased lung cancer screening rates among eligible Medicaid recipients in a rural primary care practice in North Carolina.
Use of chemotherapy among patients aged 80 years and older with metastatic non-small cell lung cancer (NSCLC) was linked to longer overall survival.
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
A deep learning model based on chest radiograph images and electronic medical record data shows promise for smokers at high risk for lung cancer
USPSTF recommends annual low-dose computed tomography screening for people aged 50 to 80 years at high lung cancer risk due to smoking history.
12.5 percent of those meeting USPSTF recommendations for low-dose CT had screening exam in past year.